Loading...
XLON
FARN
Market cap272mUSD
Dec 05, Last price  
183.00GBP
1D
0.27%
1Q
-7.34%
Jan 2017
-30.93%
IPO
-34.04%
Name

Faron Pharmaceuticals Oy

Chart & Performance

D1W1MN
XLON:FARN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.65%
Rev. gr., 5y
-61.50%
Revenues
0k
0200,000906,000520,0001,153,0001,49519,000000000
Net income
-26k
L-99.92%
-2,460,000-1,508,000-1,364,000-6,188,000-9,294,000-21,060,000-20,086,000-13,262,000-16,946,000-21,194,000-30,034,000-30,944,000-25,920
CFO
-23m
L-3.51%
-2,268,000-768,000-389,000-7,146,000-8,452,000-18,363,000-20,525,000-11,523,000-17,479,000-22,218,000-22,993,000-23,806,000-22,971,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
URL
https://www.faron.com/
IPO date
Nov 17, 2015
Employees
40
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT